Skip to content

Cimetidine

DRUG19 trials

Sponsors

Lytix Biopharma AS, Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd., Merck Sharp & Dohme LLC, Community Research Initiative of New England, Hoag Memorial Hospital Presbyterian

Conditions

Advanced or Metastatic Non-small Cell Lung CancerAdvanced MelanomaAnatomic Stage 0 Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8

Phase 1

Phase 2

Biological Therapy in Treating Patients With Metastatic Cancer
CompletedNCT00002733
Hoag Memorial Hospital PresbyterianKidney Cancer, Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
Start: 1996-01-31End: 2000-01-31Target: 30Updated: 2011-05-11
Papillary Serous Carcinoma of the Endometrium
CompletedNCT00515073
M.D. Anderson Cancer CenterEndometrial Cancer
Start: 2001-04-30End: 2013-05-31Updated: 2014-07-03
Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel
CompletedNCT04862585
Ohio State University Comprehensive Cancer CenterAnatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8 +22
Start: 2021-10-07End: 2024-06-21Updated: 2025-08-20
Effect of Oral Cimetidine in the Protoporphyrias
CompletedNCT05020184
Amy K. Dickey, M.D.Erythropoietic Protoporphyria, X-linked Protoporphyria
Start: 2022-06-14End: 2025-04-24Updated: 2026-01-21
A Phase 2 Study of Intratumoral Injection of LTX-315 in Combination with Pembrolizumab in Patients with Percutaneously Accessible Lesions with Advanced Melanoma Refractory to PD-1/PD-L1 Inhibitor Therapy
CompletedCTIS2022-500628-31-00
Lytix Biopharma ASAdvanced Melanoma
Start: 2022-10-24End: 2025-06-13Target: 22Updated: 2024-03-11
A Phase II Study of SKB264 as Monotherapy or as Combination Therapy in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer
Active, not recruitingCTIS2023-507270-41-00
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.Advanced or Metastatic Non-small Cell Lung Cancer
Start: 2024-11-22Target: 46Updated: 2025-07-29
A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable /Metastatic Solid Tumors Who are Refractory to Available Standard Therapies
CompletedCTIS2023-508700-38-00
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.Metastatic or locally advanced unresectable solid tumors progressing after available standard therapies
End: 2024-12-10Target: 31Updated: 2024-06-20

Phase 3

Unknown Phase

Related Papers